Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

or the three months to September 30, 2011 (2010: $0.4 million) and $1.4 million for the nine months to September 30, 2011 (2010: $1.3 million). R&D costs include intangible assets impairment charges of $16.0 million for the three months and nine months to September 30, 2011 (2010: $nil). SG&A costs include amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $46.4 million for the three months to September 30, 2011 (2010: $73.9 million) and $119.1 million for the nine months to September 30, 2011 (2010: $142.3 million).

Unaudited US GAAP results for the three months and nine months to September 30, 2011
Consolidated Statements of Income (continued)

3 months to 3 months to 9 months to 9 months to September September September September 30, 30, 30, 30, 2011 2010 2011 2010 Earnings per ordinary share - basic 35.0c 17.6c 110.6c 77.4c Earnings per ADS - basic 105.0c 52.8c 331.8c 232.2c Earnings per ordinary share - diluted 33.9c 17.3c 106.7c 76.0c Earnings per ADS - diluted 101.7c 51.9c 320.1c 228.0c Weighted average number of shares: Millions Millions Millions Millions Basic 551.3 547.0 551.2 546.1 Diluted 593.8 556.7 595.0 589.7

Unaudited US GAAP results for the three months and nine months to September 30, 2011
Consolidated Statements of Cash Flows

3 months to 9 months to September 30, September 30, 2011 2010 2011 2010 $M $M $M $M CASH FLOWS FROM OPERATING ACTIVITIES: Net income 192.9 96.3 609.7 422.7 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 80.0 60.0 212.3 189.2 Share based compensation 19.8 17.5 54.7 44.2 Impairment of intangible assets 16.0 42.7 16.0 42.7 Gain on sale of non-current investments (23.5) - (23.5) (11.1) Loss/(gain) on sale of product rights 0.3 - 3.8 (4.1) Other 11.7 (5.7) 5.9 5.2 Movement in deferred taxes (30.9) (10.0) (13.2) 48.7 Equi
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... ULURU Inc. (Amex:,ULU) today announced that it ... Food and Drug Administration (FDA) for Altrazeal(TM) Silver., ... have shown that,superior healing rates in numerous porcine ... dressings. Additionally, in toxicology and,in vitro bacteria inhibition ...
... (DIA) will host two co-located conferences from October 23-24 ... ... Horsham, PA (PRWEB) September 30, 2008 -- ... co-located conferences from October 23-24 in Washington DC. ...
... 30 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) ... on October 3, 2008. The investor day will provide ... regulatory milestones,for the Company. Additionally, Alessandro Gianni, M.D., Director ... University of Milan,who has authored over 300 publications will ...
Cached Biology Technology:ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 2ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver 3DIA Co-located Conference to Examine Outsourcing and Project Management Best Practices 2Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008 2
(Date:4/18/2014)... survey of emergency contraceptive pills in Peru found ... either of substandard quality or falsified. Many pills ... the wrong active ingredient. One batch had no ... the fake drugs, researchers at the Georgia Institute ... spectrometry to quickly assess suspected counterfeit drugs and ...
(Date:4/18/2014)... sprout as soon as they,re planted may be good news ... careful. In the wild, a plant whose seeds sprouted at ... More than just an insurance policy against late frosts or ... long-term advantages too: Plants whose seeds put off sprouting ... finds in a team of researchers working at the National ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... (SSB) and Adolf Kühner AG ,- Prototype of orbital ... Mai 2009 / b3c newswire / – ExcellGene ... biopharmaceutical industry, expands its product offering with the introduction ... rely on orbital shaking principles for mixing compared ...
... a patient,s healthy tissue as well as eradicating the ... especially invasive and often causing nasty side effects. ... more precise and accurate treatment for cancerous tumours by ... Real-time image-guided radiotherapy, combining radiation treatment with non-invasive MR ...
... Medical College of Georgia nurse researcher is among the first ... funding through the American Recovery and Reinvestment Act of 2009. ... jobs and the research of African-Americans in the Augusta community ... seeks to create or save more than 3.5 million jobs ...
Cached Biology News:ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 2ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor 3MCG researcher among first to receive NIH stimulus funding 2
Troponin I (22B11)...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... and pressurized syringe holder for any researcher who ... rate Microinjecting Fine microliter delivery ... to any new or existing perfusion rig - ... Connect to house air or a compressor (30 ...
Biology Products: